Drug Trial Radar · NCT05420922
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
Last checked: Nov 20, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,000
Planned (sponsor's estimate)
Start
Nov 1, 2021
Primary completion
Aug 30, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 15, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously threatens the lives and health of the people. The investigators establish multi-center, retrospective research methods, collecting the data of HCC treatment with system treatment (ICIs and TKIs) plus or without local treatment in the last 3 years, comprehensive assessment of their efficacy and safety, explore whether the efficacy of system treatment combination local treatment showed better effect compared with system or local monotherapy. Our study will find a new way to improve the prognosis of HCC patients.
Conditions
- Hepatocellular Carcinoma
- Programmed Cell Death 1
- Effects of Immunotherapy
Interventions
Lenvatinib Oral ProductDrug
Lenvatinib or Sorafenib
PD-1 inhibitorDrug
Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
Local treatmentProcedure
Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The objective response rate (ORR)Time frame: 8 weeks
- The overall survival (OS)Time frame: 12 months
- The treatment-related adverse events (TRAEs)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.